首页> 外文OA文献 >Human safety and pharmacokinetics of a single intramuscular dose of a novel spectinomycin analog, trospectomycin (U-63,366F).
【2h】

Human safety and pharmacokinetics of a single intramuscular dose of a novel spectinomycin analog, trospectomycin (U-63,366F).

机译:单一肌内注射新型壮观霉素类似物trospectomycin(U-63,366F)的人体安全性和药代动力学。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In this study, local and systemic tolerance and pharmacokinetics of trospectomycin sulfate in human beings were evaluated for the first time. Trospectomycin sulfate (U-63,366F; trospectomycin) or sterile saline was administered to 96 healthy male volunteers in doses ranging from 0.25 ml (75 mg) to 3.3 ml (1,000 mg) in a single intramuscular injection in a double-blind, randomized design. Volunteers were screened to establish baseline vital signs and laboratory test values. Pain and tenderness at the injection site, which occurred at doses of 450 mg and above, were the most common side effects; they were mild in severity and transient. Adverse drug experiences reported by subjects included nausea, dizziness, light-headedness, diaphoresis, costal pain, and perioral numbness. The perioral numbness (paresthesia) experienced at doses of 750, 900, and 1,000 mg was probably drug related. No Clostridium difficile toxin was detected in fecal samples. Pharmacokinetic calculations based on data obtained by high-performance liquid chromatography showed that after a 1,000-mg intramuscular dose of trospectomycin (3.3 ml), the serum mean half-life was 1.85 h (1.70 to 2.02 h), mean area under the serum concentration-time curve was 140.2 micrograms.h/ml and was linear with dose, mean peak concentration was 28.3 micrograms/ml (20.4 to 34.7 micrograms/ml), mean time to maximum concentration was 71 min (30 to 120 min), and the elimination rate constant was 0.307 h-1. The elimination rate constant and half-life did not vary with dose. Little trospectomycin was detected in 2-day fecal collections. A few randomly occurring abnormal clinical laboratory test values and vital signs were observed. For the trospectomycin-treated group, creatinine phosphokinase increased substantially for 24 h after injection and then decrease through day 5, while serum glutamic oxalacetic transaminase and lactate dehydrogenase increased slightly.
机译:在这项研究中,首次评估了硫酸托普卡星在人体内的局部和全身耐受性以及药代动力学。以双盲,随机设计的单次肌内注射方式,以0.25 ml(75 mg)至3.3 ml(1,000 mg)的剂量向96名健康男性志愿者施用硫酸Trospectomycin(U-63,366F; trospectomycin)或无菌盐水。 。筛选志愿者以确定基线生命体征和实验室测试值。最常见的副作用是注射部位的疼痛和压痛,发生于450 mg及以上。他们的病情轻重且短暂。受试者报告的不良药物经历包括恶心,头晕,头晕,发汗,肋痛和口周麻木。 750、900和1,000 mg的剂量引起的口周麻木(感觉异常)可能与药物有关。在粪便样品中未检测到艰难梭菌毒素。根据通过高效液相色谱获得的数据进行的药代动力学计算表明,肌肉注射剂量trospectomycin(3.3 ml)的剂量为1,000 mg后,血清平均半衰期为1.85 h(1.70至2.02 h),血清浓度下的平均面积时曲线为140.2微克.h / ml,与剂量呈线性关系,平均峰浓度为28.3微克/ml(20.4至34.7微克/ ml),达到最大浓度的平均时间为71分钟(30至120分钟),并且消除速率常数为0.307 h-1。消除速率常数和半衰期不随剂量而变化。在为期2天的粪便收集物中几乎未检出Trospectomycin。观察到一些随机发生的异常临床实验室测试值和生命体征。对于经Trospectomycin治疗的组,肌酐磷酸激酶在注射后24小时内显着增加,然后在第5天下降,而血清谷氨酸草酰乙酸转氨酶和乳酸脱氢酶则略有增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号